Smooth Muscle Contraction Mechanism: Calcium-Calmodulin-MLCK Pathway Explained

Smooth muscle contraction differs fundamentally from skeletal muscle in its calcium source, regulatory proteins, and phosphorylation-dependent mechanism.

Stepwise Mechanism

1. Stimulus & Calcium Entry
   • Agonist (norepinephrine, angiotensin II, endothelin) → GPCR → PLC → IP₃ + DAG.
   • IP₃ → SR Ca²⁺ release (minor in vascular SM).
   • Primary: Voltage-gated (L-type) and receptor-operated Ca²⁺ channels (ROCC) → extracellular Ca²⁺ influx.
   • Also: Store-operated Ca²⁺ entry (SOCE) via STIM/Orai.
2. Calcium-Calmodulin Complex Formation
   • Ca²⁺ binds calmodulin (CaM) (4 Ca²⁺/CaM).
   • Ca²⁺-CaM undergoes conformational change.
3. MLCK Activation
   • Ca²⁺-CaM binds and activates myosin light chain kinase (MLCK).
   • MLCK phosphorylates serine-19 on myosin light chain (MLC₂₀).
4. Cross-Bridge Cycling
   • Phospho-MLC → conformational change in myosin head → binds actin.
   • ATP hydrolysis → power stroke → filament sliding → contraction.
5. Relaxation
   • MLC phosphatase (MLCP) dephosphorylates MLC → relaxation.
   • Regulated by: RhoA/ROCK (inhibits MLCP → Ca²⁺ sensitization), PKG/PKA (activate MLCP → Ca²⁺ desensitization), CPI-17, telokin.

Key Differences from Skeletal Muscle

Latch State (Unique to Smooth Muscle)

Dephosphorylated myosin remains attached to actin ("latch bridges"), maintaining force with minimal ATP consumption. Critical for sustained vascular tone.

Clinical Relevance

• Vasodilators: NO → cGMP → PKG → MLCP activation; CCBs block Ca²⁺ entry.
• Bronchodilators: β₂-agonists → cAMP → PKA → MLCP activation.
• Uterine relaxants: Magnesium sulfate, nifedipine, β-agonists (tocolysis).

Understanding this pathway underpins treatment of hypertension, asthma, preterm labor, and erectile dysfunction.